Difference between revisions of "Rho(D) immune globulin (RhoGAM)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
Line 15: | Line 15: | ||
<references/> | <references/> | ||
− | [[Category: | + | [[Category:Drugs]] |
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
[[Category:Immune thrombocytopenic purpura (ITP) medications]] | [[Category:Immune thrombocytopenic purpura (ITP) medications]] |
Revision as of 22:49, 13 June 2018
General information
Class/mechanism: Not entirely known. Rho(D) immune globulin forms anti-D-coated red blood cell complexes which are thought to bind to macrophage receptors in the spleen. This is then hypothesized to block the spleen's clearance of antibody-coated cells, which include platelets. Thus, the destruction of platelets in ITP is limited.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.